UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000028055
Receipt number R000032101
Scientific Title Phase II study of FOLFIRINOX for unresectable pancreatic cancer patients after discontinuation of Pegfilgrastim
Date of disclosure of the study information 2017/07/04
Last modified on 2019/06/22 16:17:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of FOLFIRINOX for unresectable pancreatic cancer patients after discontinuation of Pegfilgrastim

Acronym

Discontinuation of PegG

Scientific Title

Phase II study of FOLFIRINOX for unresectable pancreatic cancer patients after discontinuation of Pegfilgrastim

Scientific Title:Acronym

Discontinuation of PegG

Region

Japan


Condition

Condition

Unresectable pancreatic cancer

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety and effectiveness of discontinuation of pegfilgrastim for unresectable pancreatic cancer patients receiving FOLFIRINOX with pegfilgrastim

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

incidence of febrile neutropenia during the first 2 cycles of FOLFIRINOX

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Discontinuation of Pegfilgrastim

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >

Gender

Male and Female

Key inclusion criteria

1)Histologically or cytologically proved pancreatic adenocarcinoma or adenosquamous carcinoma
2)Receiving >=2cycles of FOLFIRINOX with pegfilgrastim and no findings of FN
3)Age >=20, <75
4)ECOG Performance Status 0-1
5)Life expectancy >=12weeks
6)Meets the following criteria within 7days before enrollment
1. absolute neutrophil: >=2,000/mm3
2. platelet count: >=100,000/mm3
3. total bilirubin: =<2.0 mg/dL
7)No progressive radiological findings within 14days before enrollment.
8)Tumor is regarded as unresectable.
9)With appropriate drainage for obstructive jaundice
10)Written informed consent to participate in this study

Key exclusion criteria

1)Severe myelosuppression
2)Active infection (except viral hepatitis)
3)Serious complications (organ failure, or active peptic ulcer etc)
4)Severe diarrhea
5)Intestinal pneumonitis or pulmonary fibrosis
6)Treatment-resistant ascites or pleural effusion
7)Brain or meningeal metastasis
8)Pregnancy or breast-feeding
9)Any contraindication for FOLFIRINOX
10)Severe complication by administration of pegfilgrastim
11)Severe mental disorder, or central nervous system disorders
12)Contraindication for dynamic CT/MRI
13)Inappropriate for this study judged by the investigator

Target sample size

33


Research contact person

Name of lead principal investigator

1st name Tatsuya
Middle name
Last name Yamashita

Organization

Kanazawa University Hospital

Division name

Department of Gastroenterology

Zip code

920-8641

Address

13-1, Takaramachi, Kanazawa, Japan

TEL

076-265-2235

Email

ytatsuya@m-kanazawa.jp


Public contact

Name of contact person

1st name Takeshi
Middle name
Last name Terashima

Organization

Kanazawa University Hospital

Division name

Department of Gastroenterology

Zip code

920-8641

Address

13-1, Takaramachi, Kanazawa, Japan

TEL

076-265-2235

Homepage URL


Email

tera@m-kanazawa.jp


Sponsor or person

Institute

Kanazawa University Hospital

Institute

Department

Personal name



Funding Source

Organization

Kanazawa University Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Certified Review Board, Kanazawa University

Address

13-1, Takaramachi, Kanazawa, Japan

Tel

076-265-2048

Email

crc.irb-knz@esct.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 07 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2017 Year 07 Month 01 Day

Date of IRB

2017 Year 06 Month 29 Day

Anticipated trial start date

2017 Year 07 Month 10 Day

Last follow-up date

2022 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 07 Month 03 Day

Last modified on

2019 Year 06 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032101


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name